A PK/PD study of Delta-4 abiraterone metabolite in metastatic castration-resistant prostate cancer patients-Reference-Cited by-同舟云学术

A PK/PD study of Delta-4 abiraterone metabolite in metastatic castration-resistant prostate cancer patients

Published:2018-10 Issue: Volume:136 Page:56-61
ISSN:1043-6618
Container-title:Pharmacological Research
language:en
Short-container-title:Pharmacological Research

Author:

Blanchet Benoit,Carton Edith,Alyamani Mohammad^ORCID,Golmard Lisa,Huillard Olivier^ORCID,Thomas-Scheomann Audrey,Vidal Michel,Goldwasser François,Sharifi Nima,Alexandre Jérôme

Publisher

Elsevier BV

Subject

Pharmacology

Reference19 articles.

1. Metastatic prostate cancer;Sartor;N. Engl. J. Med.,2018

2. Abiraterone and increased survival in metastatic prostate cancer;de Bono;N. Engl. J. Med.,2011

3. Abiraterone in metastatic prostate cancer without previous chemotherapy;Ryan;N. Engl. J. Med.,2013

4. Abiraterone for prostate cancer not previously treated with hormone therapy;James;N. Engl. J. Med.,2017

5. Relation between plasma trough concentration of abiraterone and prostate-specific antigen response in metastatic castration-resistant prostate cancer patients;Carton;Eur. J. Cancer,2017

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Intra-individual Dose Escalation of Abiraterone According to Its Plasma Exposure in Patients with Progressive Metastatic Castration-Resistant Prostate Cancer: Results of the OPTIMABI Trial;Clinical Pharmacokinetics;2024-07

2. Long-Term Pharmacokinetic Follow-Up of Abiraterone Acetate in Patients with Metastatic Castration-Resistant Prostate Cancer;International Journal of Molecular Sciences;2024-05-31

3. New-generation androgen receptor signaling inhibitors (ARSIs) in metastatic hormone-sensitive prostate cancer (mHSPC): pharmacokinetics, drug-drug interactions (DDIs), and clinical impact;Expert Opinion on Drug Metabolism & Toxicology;2024-05-22

4. Olaparib plus Abiraterone for Metastatic Castration-resistant Prostate Cancer: Pharmacokinetics Data from the PROpel Trial;European Urology Oncology;2023-10

5. Pharmacogenetics and Pharmacogenomics in Precision Medicine;Oncology: Genomics, Precision Medicine and Therapeutic Targets;2023